In 2018, a high school football player in Pike County, Georgia dropped to the ground during the third quarter of a game.

Officials initially thought he had sustained a leg injury… but just minutes after limping off the field, he fell off the bench.

Trainers and coaches called for help as he drifted in and out of consciousness. And he was rushed to a hospital.

Over 45 hours, doctors fought to save the young man’s life. Ultimately, he died from cardiac arrest caused by a closed head injury.

The most shocking detail: The young man hadn’t suffered a major blow to his head. It was a relatively minor jolt – missed by trainers and medical staff – that cost him his life.

The condition that led to the young teen’s death is called traumatic brain injury (TBI).

TBI is caused by a blow, jolt, or penetration to the head that disrupts normal brain function. Major causes of TBI include car crashes, sports injuries, construction site accidents, and acts of violence.

Symptoms include headaches… slurred speech, impaired motor functions like imbalance… and sensory changes to hearing, taste, and sight.

The condition can also lead to concussions, coma, and even death.

According to the American Association of Neurological Surgeons, nearly 2.5 million people in the United States will be admitted to an emergency room this year for TBI.

And unfortunately, about five million Americans suffer permanent disabilities from TBI. The CDC estimates the total medical costs of TBI are about $76.5 billion per year.

It’s a huge problem… And the people who are working on a solution may surprise you… and in the process, make life-changing gains for early investors.

A Mental Health Breakthrough

Despite the number of cases, TBI is still one of the most poorly understood mental disorders. But one area of medical science is stepping up to the plate…

I’m talking about psychedelics.

Despite recent scientific research showing the efficacy of psychedelic medicines… when most people hear about them, they immediately think about party drugs.

Things like psilocybin (“magic mushrooms”), LSD (“acid”), or MDMA (“ecstasy”).

Yet, the irony is that some of these oft-demonized drugs not only have very legitimate medical purposes… they may actually help treat TBI and related injuries.

In particular, psilocybin has shown the potential to improve the health and wellness of patients suffering from brain injuries.

Derived from so-called “magic” mushrooms, psilocybin binds to serotonin receptors in the brain. It creates effects of euphoria and changes in perception and sense of time.

At certain doses, psilocybin elicits profound changes in consciousness and has great potential in treating mental health disorders. It’s being used to treat mental disorders like depression, anxiety, and substance abuse.

In 2018, the FDA granted a “breakthrough therapy” designation to Compass Pathways, which is using psilocybin for treatment-resistant depression (TRD).

And in 2019, the FDA gave the same designation to the Usona Institute, which uses psilocybin to treat major depressive disorder (MDD). The disorder causes a persistent feeling of sadness and loss of interest

Today, pharmaceutical companies are working on psilocybin formulations to treat TBI. And the results are promising.

One person in our network used a cocktail of psilocybin and other non-psychoactive compounds… And after six months of treatment, he’d finally found the lasting relief from years of TBI symptoms.

These therapies are still in their early stages of development. And some haven’t even started preclinical trials yet. But that’s the opportunity in front of us.

You can take a small stake and position yourself in these types of companies today – and if they become breakthrough drugs – potentially move the needle on your net worth.

Be Early, Be Right

Psychedelics are helping to solve a global mental health epidemic that costs society an estimated $3 trillion in health expenses and lost productivity.

That’s why Daily editor Teeka Tiwari calls this trend his next “trillion-dollar trade.” And you still have a chance to get in early… and position yourself in the right companies.

You see, individual investors have an early advantage over institutions. That’s because institutions must wait until stocks are large enough to trade on the world’s biggest exchanges.

This allows you to get in before the institutions… And puts you way ahead as these companies grow and a flood of money finds its way into this space.

We saw a similar scenario play out when early investors made fortunes by entering the crypto market before institutions. Once crypto adoption started to take off, certain tiny tokens exploded.

So, if you’re looking to take advantage of the opportunity in psychedelic therapeutics, my advice is to get positioned right now… before Wall Street can participate.

One way to get broad exposure to this trend is through the Defiance Next Gen Altered Experience ETF (PSY). It holds a basket of companies working on psychedelic and cannabis-based therapeutics.

These are early-stage companies on the very cutting-edge of the biotech space. That means there’s a significant risk that some will fail to see their therapies reach the mass market.

PSY spreads this risk out across many different companies in this space… but always remember to do your homework before investing… and never invest more than you’re willing to lose.

Invest with conviction,

Anthony Planas signature

Anthony Planas
Analyst, Palm Beach Daily

P.S. Psychedelic medicine isn’t the only trillion-dollar trend still in its early stages… Cryptos are another.

And right now, one of the biggest opportunities we see outside of the psychedelic space is blockchain projects.

At their current pace, these projects could become the No.1 investment of the decade… like buying Microsoft in the ‘80s… Amazon in the ‘90s… and bitcoin in 2010.

That’s why Teeka recently shared the details of this No. 1 investment in an exclusive interview.

Click here to watch.